Results 11 to 20 of about 8,778 (220)
Potential use of [gammadelta] T cell-based vaccines in cancer immunotherapy [PDF]
Frontiers in Immunology, 2014 Immunotherapy is a fast advancing methodology involving one of two approaches: 1) compounds targeting immune checkpoints, and 2) cellular immunomodulators.
Mohd Wajid A. Khan +2 more
doaj +5 more sources
Direct and Indirect Effects of Cytomegalovirus-induced gamma-delta T Cells after Kidney Transplantation [PDF]
Frontiers in Immunology, 2015 Despite effective anti-viral therapies, cytomegalovirus (CMV) is still associated with direct (CMV disease) and indirect effects (rejection and poor graft survival) in kidney transplant recipients.
Lionel eCouzi +5 more
doaj +3 more sources
SPP1 May Play an Important Role in the Carcinoid Nature of PAH. [PDF]
Mediators InflammObjection Pulmonary arterial hypertension (PAH) was a cancer‐like disease. It shared several mechanisms, including perivascular inflammation. But the genes common and different between cancer and PAH was still unclear. We aimed to analyze the genes common in the two diseases, especially the N7‐methylguanosine (m7G) genes.
Huang Y, Yan S, Zhu J, Zhang W.
europepmc +2 more sources
Th1/Th17 gammadelta T cells are expanded in HIV-1 infected patients and respond to Candida albicans [PDF]
Retrovirology, 2010 Poggi A +7 more
europepmc +2 more sources
NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors. [PDF]
PLoS Pathogens, 2010 NK and gammadelta T cells can eliminate tumor cells in many experimental models, but their effect on the development of tumors caused by virus infections in vivo is not known.
Rabinarayan Mishra +3 more
doaj +1 more source
Obesity and cancer: the gammadelta T cell link
Exploration of Immunology, 2022 Obesity has become a worldwide scourge, affecting more than 10% of adults worldwide. While widely recognized to be associated with increased incidence of medical conditions such as diabetes mellitus and atherosclerosis, obesity also accounts for 9% of ...
Ilan Bank
doaj +1 more source
American Journal of Hematology, Volume 98, Issue 11, Page 1699-1710, November 2023., 2023 The CAR‐HEMATOTOX risk‐stratifies for toxicity and survival in relapsed/refractory MCL. Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel) has substantially improved treatment outcomes for patients with relapsed/refractory mantle cell lymphoma (r/r MCL).
Kai Rejeski +19 more
wiley +1 more source
HemaSphere, Volume 7, Issue 8, August 2023., 2023 Real‐world evidence suggests a trend toward inferior survival of patients receiving CD19 chimeric antigen receptor (CAR) T‐cell therapy in Europe (EU) and with tisagenlecleucel. The underlying logistic, patient‐ and disease‐related reasons for these discrepancies remain poorly understood.
Veit Bücklein +26 more
wiley +1 more source
The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. [PDF]
PLoS ONE, 2009 The phosphopeptide P140 issued from the spliceosomal U1-70K snRNP protein is recognized by lupus CD4(+) T cells, transiently abolishes T cell reactivity to other spliceosomal peptides in P140-treated MRL/lpr mice, and ameliorates their clinical features.
Nicolas Page +9 more
doaj +1 more source
Cancer Medicine, Volume 12, Issue 9, Page 11020-11039, May 2023., 2023 PLK1 regulated the degree of immune cell (e.g., CD8+ T cells, Tregs, etc.) infiltration and immunomodulator expressions, thus participating in the tumor‐specific immune response. The PLK1‐based immune risk model could accurately identify immunotherapy‐or chemotherapy‐sensitive breast cancer patients, which is expected to act as a biomarker for ...
Yan Chen +6 more
wiley +1 more source